TPCW
AZN icon

TD Private Client Wealth’s AstraZeneca AZN Stock Holding History

TD Private Client Wealth’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08M Sell
5,750
-3,256
-36% -$612K 0.02% 355
2026
Q1 		$1.74M Sell
9,006
-798
-8% -$154K 0.04% 271
2025
Q4 		$1.8M Sell
9,804
-538
-5% -$94.4K 0.04% 265
2025
Q3 		$1.59M Buy
10,342
+277
+3% +$41.9K 0.04% 280
2025
Q2 		$1.41M Buy
10,065
+681
+7% +$95.4K 0.03% 297
2025
Q1 		$1.38M Buy
9,384
+980
+12% +$142K 0.04% 286
2024
Q4 		$1.1M Buy
8,404
+3,100
+58% +$434K 0.03% 337
2024
Q3 		$826K Sell
5,304
-700
-12% -$113K 0.02% 387
2024
Q2 		$937K Sell
6,004
-692
-10% -$104K 0.03% 355
2024
Q1 		$907K Sell
6,696
-10
-0.1% -$1.32K 0.03% 361
2023
Q4 		$903K Buy
6,706
+490
+8% +$63.7K 0.03% 342
2023
Q3 		$842K Sell
6,216
-1,621
-21% -$221K 0.04% 336
2023
Q2 		$1.12M Sell
7,837
-842
-10% -$124K 0.05% 312
2023
Q1 		$1.2M Sell
8,679
-4,331
-33% -$583K 0.05% 297
2022
Q4 		$1.76M Buy
13,010
+50
+0.4% +$6.27K 0.08% 237
2022
Q3 		$1.42M Sell
12,960
-813
-6% -$103K 0.07% 250
2022
Q2 		$1.82M Sell
13,773
-665
-5% -$87.3K 0.09% 223
2022
Q1 		$1.92M Buy
14,438
+450
+3% +$54K 0.08% 242
2021
Q4 		$1.63M Buy
13,988
+1,751
+14% +$206K 0.07% 271
2021
Q3 		$1.47M Buy
12,237
+666
+6% +$77.5K 0.06% 282
2021
Q2 		$1.39M Buy
11,571
+1,704
+17% +$187K 0.06% 290
2021
Q1 		$981K Buy
9,867
+123
+1% +$12.4K 0.05% 316
2020
Q4 		$974K Buy
9,744
+201
+2% +$21.3K 0.05% 305
2020
Q3 		$1.05M Sell
9,543
-4,491
-32% -$500K 0.06% 285
2020
Q2 		$1.48M Buy
14,034
+660
+5% +$68.2K 0.09% 223
2020
Q1 		$1.19M Buy
13,374
+2,161
+19% +$203K 0.09% 201
2019
Q4 		$1.12M Buy
+11,213
New +$1.06M 0.07% 257

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

TD Private Client Wealth's AZN Position: Q2 2026 in Review

TD Private Client Wealth reduced its AstraZeneca (AZN) stake by 36% in Q2 2026, selling an estimated $612K and leaving 5,750 shares worth $1.08M. The position accounts for 0.02% of the portfolio, ranked #355.

TD Private Client Wealth first reported a position in AZN in Q4 2019 and has held it in 27 quarters since. The position peaked at $1.92M in Q1 2022. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • TD Private Client Wealth held 5,750 shares of AstraZeneca worth $1.08M as of Q2 2026.
  • TD Private Client Wealth sold 3,256 AstraZeneca shares in Q2 2026, an estimated $612K.
  • AstraZeneca made up 0.02% of TD Private Client Wealth's portfolio in Q2 2026, its #355 holding.
  • TD Private Client Wealth first reported a position in AstraZeneca in Q4 2019 and has held it in 27 quarters since.
  • TD Private Client Wealth's AstraZeneca position peaked at $1.92M in Q1 2022.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.